Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : CAL02
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Eagle Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the Agreement, Eagle will be solely responsible for further clinical development of CAL02, consists of liposomes that capture and neutralize bacterial toxins produced by a broad range of Gram-positive and Gram-negative bacteria.
Product Name : CAL02
Product Type : Antibiotic
Upfront Cash : Undisclosed
August 25, 2021
Lead Product(s) : CAL02
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Eagle Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Reset All
